The overall 5-year survival for pancreatic cancer has changed little over the past few
decades, and pancreatic cancer is predicted to be the second leading cause of cancer …

Thanks to the development of modern chemotherapeutic regimens, survival after surgery for
pancreatic ductal adenocarcinoma (PDAC) has improved and pancreatologists worldwide …

Objective: For patients with locally advanced and unresectable pancreatic cancer (PDAC),
neodadjuvant treatment and consecutive surgical exploration have been studied during the …

Pancreatic cancer is a major cause of cancer-associated mortality, with a dismal overall
prognosis that has remained virtually unchanged for many decades. Currently, prevention or …

Pancreatic ductal adenocarcinoma (PDAC) is clinically challenging due to late diagnosis
and resistance to therapy. Two major PDAC subtypes have been defined based on …

Objective To assess clinical and pathologic efficacy of neoadjuvant FOLFIRINOX for locally
advanced (LAPC) and borderline resectable pancreatic cancer (BRPC). Methods Patients …

Two areas that remain the focus of improvement in pancreatic cancer include high post-
operative morbidity and inability to uniformly translate surgical success into long-term …

Background The prognosis of initially unresectable pancreatic cancer (UR-PC) has
improved since the introduction of FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel …

Purpose Chemotherapy with or without radiotherapy is the standard in patients with initially
nonmetastatic unresectable pancreatic cancer. Additional surgery is in discussion. The …

Background Outcomes of neoadjuvant systemic therapy versus an upfront operation for
clinical, stage III pancreatic adenocarcinoma remain poorly defined. Our aim was to …